RCT: Semaglutide significantly improves symptoms and weight loss in HFpEF and type 2 diabetes patients

This randomized clinical trial evaluated the effects of semaglutide on 616 patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes. Patients received weekly doses of 2.4 mg semaglutide or a placebo for 52 weeks. The study’s primary findings included a significant improvement in heart failure–related symptoms, as measured by the Kansas City Cardiomyopathy Questionnaire clinical summary score (average increase of 13.7 points in the semaglutide group versus 6.4 points in the placebo group). Additionally, semaglutide treatment resulted in a mean 9.8% reduction in body weight compared to 3.4% with placebo. Secondary outcomes also favored semaglutide, showing enhancements in 6-minute walk distance and reductions in C-reactive protein levels. Notably, semaglutide was associated with fewer serious adverse events compared to placebo.

Reference (link to abstract – $ for full-text):

Mikhail N. Kosiborod et al. (2024). Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med, 390(15), 1394-1407. DOI: 10.1056/NEJMoa2313917